The role of virological monitoring A clinical perspective Eric Goemaere MSF South Africa.

Slides:



Advertisements
Similar presentations
Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.
Advertisements

1 AIDS EPIDEMIC IN COTE DIVOIRE TCHOMIAN Clement ADJE Technical Advisor, for care and support EGPAF.
Hopital Pitié Salpérière
TB and HIV Management Dr A.L. Pozniak Chelsea and Westminster Hospital London, UK.
1 TREATMENT AND PREVENTION SCALE-UP: THE SOUTH AFRICAN EXPERIENCE By Dr Moolman Team South Africa.
HIV Situation in India Dr Sunil Gaikwad.
1. 2 Why are Result & Impact Indicators Needed? To better understand the positive/negative results of EC aid. The main questions are: 1.What change is.
World Health Organization Surveys of Transmitted and Acquired HIV Drug Resistance in Resource Limited Settings CROI 2011 S Bertagnolio*, K Kelley*, A Saadani.
Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
0 - 0.
No Goals at Half-time: What Next for the Millennium Development Goals? Goal 6: Combating HIV/AIDS, malaria and other diseases John Porter.
Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.
Cost of HIV/AIDS Adult and Pediatric Clinical Care and Treatment in Ghana Felix Asante, Jim Rosen, Futures Group/HPI August 4, 2010 Accra.
Exploring Synergies Health Systems and Sustainability TB/HIV collaboration Alasdair Reid UNAIDS Pretoria International Multistakeholder Consultation on.
WHO Guidelines and future perspectives for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Twenty-four month outcome of the PASER cohort: what happens to patients failing ART? Pascale Ondoa Sonia Boender.
The Future of HIV Diagnostics: Market Trends for CD4 and VL Testing Decade of Diagnostics Satellite Kuala Lumpur July 2, 2013.
CD4 and VL Monitoring: Research and Development needs and Policy implications Monitoring ART session XVIII IAC Vienna 2010 Prof Charles Gilks UNAIDS India.
25 seconds left…...
Equal or Not. Equal or Not
HIV/AIDS and Women: An Overview Global HIV/AIDS and Women: Current Challenges and Opportunities Briefing, Rayburn House Office Building Jen Kates, PhD.
Loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi: Understanding outcomes and reasons Hannock Tweya, Salem Gugsa, Mina Hosseinipour,
KZN STUDY –UPDATE South African ART Resistance Cohort Studies (SARCS)
Feasibility and acceptability of an antiretroviral treatment as prevention (TasP) intervention in rural South Africa Results from the ANRS TasP cluster-randomised.
Affordable Resistance Testing for Africa (ART-A)
Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.
HIV and AIDS Data Hub for Asia-Pacific Review in slides Children Last updated: February 2015.
Craig McClure Chief, HIV and AIDS section NYHQ Workshop on ART in Pregnancy, Breastfeeding and Beyond Johannesburg, South Africa, June 18-20, 2012 Planning.
The UNITAID-funded MSF diagnostics project: Plans to incorporate the new WHO recommendations and how best practices will be shared with, and disseminated.
Preliminary findings of a routine PMTCT Option B+ programme in a rural district in Malawi Rebecca M. Coulborn 1, Laura Triviño Duran 1, Carol Metcalf 2,
Community models of ART delivery in Southern Africa MSF Regional experience E. Goemaere, Medecins Sans Frontieres IAS Washington, July 26 th 2012.
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
3 rd South African AIDS Conference, Durban 2007 Plugging the leaky cascade, Rome IAS, July 2011 Plugging the Leaky Cascade: Programmatic adjustments for.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
Challenges in adapting chronic HIV/TB services to high mobile populations in Southern Africa Eric Goemaere, MD Médecins Sans Frontières IAS Washington,
Evaluation of the WHO immunologic criteria for treatment failure among adults on first-line HAART in south India Snigdha Vallabhaneni 1, Sara Chandy 2,
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
2 3 Population : 6,934,169 inhabitants 6 Sanitary regions UNAIDS (2014) - HIV prevalence : 2.5% = 110,000 PLHIV - Higher prevalence in southern regions.
1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Scaling up Access to HIV treatment What can we learn for NCDs?
Implementation of routine HIV viral load monitoring A multisite cascade analysis Munyaradzi Dhodho1, Marthe Frieden1, Amir Shroufi2, Esther Wanjiru3, Sarah.
Amir Shroufi Medical Coordinator MSF South Africa
Number of people receiving antiretroviral therapy in
World Health Organization
Implementation of routine HIV viral load monitoring A multisite cascade analysis Munyaradzi Dhodho1, Marthe Frieden1, Amir Shroufi2, Esther Wanjiru3, Sarah.
ART Adherence Clubs South Africa
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Utilizing research as an opportunity to strengthen
Closing the Treatment Gap of Children Living with HIV
ART Adherence Clubs South Africa
The role of CD4 in patient monitoring Amsterdam July 2018
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Implementation of routine HIV viral load monitoring A multisite cascade analysis Munyaradzi Dhodho1, Marthe Frieden1, Amir Shroufi2, Esther Wanjiru3, Sarah.
Presentation transcript:

The role of virological monitoring A clinical perspective Eric Goemaere MSF South Africa

Treatment simplification? HIV/TB integration PHC decentralization Task shifting Simplified treatment

Impact of routine monitoring <> Immuno- clinical monitoring on regimen change Project/ Country nMedian time on ART on second line Thyolo, Malawi M0.4 % Buhera, Zimbabwe M1.6 %

VL monitoring in LIC : a love/hate story HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary? Alexandra Calmy,1,5 Nathan Ford,6 Bernard Hirschel,2 Steven J. Reynolds,7 Lut Lynen,4 Eric Goemaere,8 Felipe Garcia de la Vega,1Luc Perrin,3 and William Rodriguez9,10, CID 2007:44 HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary? Alexandra Calmy,1,5 Nathan Ford,6 Bernard Hirschel,2 Steven J. Reynolds,7 Lut Lynen,4 Eric Goemaere,8 Felipe Garcia de la Vega,1Luc Perrin,3 and William Rodriguez9,10, CID 2007:44 More accurate assessment of treatment failure will reduce the delay in switching to second-line drugs. Targeted use of VL can limit unnecessary switching and routine use of VL can reduce the risk of resistance. WHO 2010 guidelines Keiser et al, AIDS 2011

Female, CHK Kinsahsa N° , DOB 11/10/1972 Exclusive Immuno/clinical monitoring delays clinical reaction Phase IV Oesophageal candidiasis VL VL > moved to 2 nd line Cd4 < 30 % Cd4 < 50 %

Predicting virological failure ( < 30 % of nadir CD4) in adults M. Pujades, L. Pinoges, Epicentre, not published Sensitivity = 17.2% (12.3% %) Specificity = 94.5% (93.6% %) Sensitivity = 17.2% (12.3% %) Specificity = 94.5% (93.6% %) PPV = 18.5% (13.3% %) NPV = 94.0% (93.1% %) PPV = 18.5% (13.3% %) NPV = 94.0% (93.1% %)

Predicting virological failure in children – Thailand: US IF criteria to identify children with single viral load >1000 copies/ml after 1 year of treatment (n=202) Sensitivity: 15%; PPV: 16% (Jittamala et al. 2009) – Uganda: WHO IF criteria to identify children with confirmed viral load >400 copies/ml for (n=116) Sensitivity: 0% (Ruel et al. 2010) – South Africa : criteria to identify children with VL > 1000 cp/ml ( n = 2543 ) Sensitivity 5 %, PPV= 42 % ( Mary Ann Davies, Durban Aids conference June 2011) – Thailand: US IF criteria to identify children with single viral load >1000 copies/ml after 1 year of treatment (n=202) Sensitivity: 15%; PPV: 16% (Jittamala et al. 2009) – Uganda: WHO IF criteria to identify children with confirmed viral load >400 copies/ml for (n=116) Sensitivity: 0% (Ruel et al. 2010) – South Africa : criteria to identify children with VL > 1000 cp/ml ( n = 2543 ) Sensitivity 5 %, PPV= 42 % ( Mary Ann Davies, Durban Aids conference June 2011)

Impact in early detection of VF Viral load at 3 months after initiation of antiretroviral therapy is associated with better virological and treatment outcomes than at 6 months. B. Kerschberger 1, A. M. Boulle 2, K. Kranzer 3, K. Hilderbrand 1,2, M. Schomaker 2, D.Coetzee 2, E.Goemaere 4, N. Ford 2,5, G. Van Cutsem 1,2 VL3 group : 22% less likely to experience subsequent virological failure, 27% less likely to be later switched to second line regimen

If no access to VL, priorities for VL ? Steven Van Den Broucke, Sandra Simons, Katharina Kranzer Dhodho Munyaradzi, Carol Metcalf, Kwenzakwenkosi Ncube, Helen Bygrave Poster : THPE725 Thursday 26th

Impact of late viraemia detection on horizontal and vertical transmission ? Horizontal transmission Vertical transmission – PMTCT B + : danger for subsequent pregnancies Horizontal transmission Vertical transmission – PMTCT B + : danger for subsequent pregnancies p2p3p4 HIV (+): ART: LTF: 12 M** Pre-ART Facility based HCT : Enrolled in care: LTF: 6 M Out of facility HCT : LTF:

Impact of late viraemia detection on resistance building ( TAM and K65R) Source : The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral, Therapy, Mina C. Hosseinipour & all, AIDS 23:1127–1134

Conclusions Immuno/clinical monitoring do not replace virological monitoring Key challenges are around technical/ geographical / financial access to virological monitoring Unitaid/ Chai/Unicef / MSF concerted efforts will work on all 3 aspects to make virological monitoring a reality in LIC by 2015

Acknowledgements MSF & MOH teams in Zimbabwe, RDC and South Africa Helen Bygrave, Teri Roberts,Nathan Ford All the ones fighting to be ‘ viral load undetectable’

Thank You